A couple of things I have found out since my last post.
If to much of the antibody is given it will drift down to other sites. This should not be a problem.
old sales estimates - "RIGScan uses a tumor-specific targeting agent and a medical device to ensure that surgeons don't miss any part of a cancerous tumor, and is expected to generate $280 million in sales 3 years after approval (1997)
Neop has not yet collected all the data from the previously run crc trials. They collected a small portion and because of the results of the data they collected they want to meet with the FDA again. Neop intends to find out if they get a complete collection of data and the data is positive, will that data be enough to complete the BLA previously submitted.
Market Data 
Markets 
AI
